Information Provided By:
Fly News Breaks for May 9, 2018
PEN
May 9, 2018 | 07:29 EDT
Canaccord analyst Jason Mills raised his price target on Penumbra to $165 from $125 and recommended investors add to current positions. He called Penumbra one of the most productive growth companies in med-tech and said both the Neuro and Peripheral businesses accelerated, helping the company "blow away" consensus Q1 estimates. Mills reiterated his Buy rating on Penumbra shares.
News For PEN From the Last 2 Days
There are no results for your query PEN